Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by Bank of America Corporation from $36.00 to $46.00 in a research report sent to investors on Thursday.

A number of other brokerages have also recently weighed in on ASND. BidaskClub cut Ascendis Pharma A/S from a hold rating to a sell rating in a research note on Wednesday, August 9th. Leerink Swann reissued a hold rating and set a $28.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 1st. Wells Fargo & Company reissued a buy rating and set a $51.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Zacks Investment Research cut Ascendis Pharma A/S from a hold rating to a sell rating in a report on Wednesday, August 23rd. Finally, Credit Suisse Group set a $28.00 target price on Ascendis Pharma A/S and gave the company a buy rating in a report on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $35.10.

Shares of Ascendis Pharma A/S (ASND) opened at 36.25 on Thursday. Ascendis Pharma A/S has a one year low of $17.15 and a one year high of $42.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Friday, August 18th. The biotechnology company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative net margin of 2,977.70% and a negative return on equity of 67.76%. The firm had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $0.78 million. During the same period in the previous year, the firm earned ($0.53) EPS. The firm’s revenue for the quarter was down 61.4% compared to the same quarter last year. Equities research analysts expect that Ascendis Pharma A/S will post ($0.12) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/ascendis-pharma-as-asnd-given-new-46-00-price-target-at-bank-of-america-corporation/1602556.html.

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in shares of Ascendis Pharma A/S by 23.6% in the first quarter. Bank of America Corp DE now owns 5,345 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 1,020 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Ascendis Pharma A/S by 7.9% in the second quarter. Alps Advisors Inc. now owns 29,264 shares of the biotechnology company’s stock valued at $812,000 after purchasing an additional 2,144 shares during the period. Bank of Montreal Can boosted its holdings in Ascendis Pharma A/S by 127.4% in the second quarter. Bank of Montreal Can now owns 4,535 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 2,541 shares during the period. Victory Capital Management Inc. purchased a new position in Ascendis Pharma A/S in the first quarter valued at $144,000. Finally, Karp Capital Management Corp purchased a new position in Ascendis Pharma A/S in the first quarter valued at $203,000. 71.60% of the stock is currently owned by institutional investors and hedge funds.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.